Abstract:Objective:To observe the clinical efficacy and safety of combined CVVH-bilirubin adsorption treatment on patients with hyperbilirubinemia and compare to the traditional plasma separation perfusion.Methodology:Sixteen cases with hyperbilirubinemia received total 55 sessions artificial liver support therapy(ALS).All of them were treated with conventional plasma perfusion(conventional method) for the first treatment.The rate of blood flow was set at 100~120 ml/min and the rate of plasma separated was set at 30~40 ml/min.Then they were treated with combined CVVH-bilirubin adsorption(combination method).The rate of blood flow was set at 200~250 ml/min and the rate of plasma separated was set at 90 ml/min.Separated blood plasma components were filtrated by the CVVH filter AV600 when ultrafiltration rate was set at 66 ml/min.Then concentrated plasma components were adsorpted by BRS-350 adsorption column and they were reinfusioned in vivo.At the same time bicarbonate replacement fluid at the speed of 4 000 ml/hr with pre-dilution mode was input before plasma component separator EC40W.ALS was performed with 8 hours.Blood biochemistry and coagulation were measured before and after single treatment.Similarly blood biochemistry,plasma biochemistry before plasma separator and plasma biochemistry before and after BRS-350 were measured at the 0.5h,2h,4h,6h and 8h of therapy.The clinical vital signs were recorded,and the acute physiology and chronic health evaluation(APACHEII),Glasgow coma score,MELD score of liver function before and after single treatment were assessed.Results:The average reduction rate of TBL,DBL,IDBL,and TBA were(46.1±8.3)%,(47.3±8.0)%,(40.7±2.8)%,and(36.5±5.2)%,respectively,with the conventional method after single treatment and the reduction rate of TBL,DBL,IDBL,and TBA were(54.4±5.2)%,(54.2±5.3)%,(63.8±7.2)%,and(47.6±14.7)%,respectively,with combined CVVH-bilirubin adsorption after single treatment.The clearance of TBL were(22.3±2.2),(12.2±4.4),and(9.0±2.8) ml/min,respectively,with the conventional treatment at the 0.5h,2h,and 4h therapy.The clearance of TBL were(28.7±13.1),(21.9±9.1),(16.1±4.3)ml/min respectively,with combination treatment,at the time corresponding to conventional treatment.At the end of treatment,the clearance of TBL were(8.3±3.0) and(9.3±4.1) ml/min,respectively.The clearance of TBL,DBL,and IDBL was decreased with time on the course of treatment weather combined CVVH-bilirubin adsorption or conventional treatment.The concentration of on total protein(TP),albumin(ALB) were lower than before treatment and APTT,PT,and INR were longer with conventional treatment.But blood BUN,SCr,ALT,and AST were decreased and there were no effect on TP,ALB and coagulation with combination method after single treatment.The survival rate was 69% in ICU at 30-day and 56% in discharging from hospital.During the treatment,the vital signs of all patients were stable and there were no adverse events.Conclusion:The combined CVVH-bilirubin adsorption therapy is a novel and effective artificial liver support therapy.It can significantly reduce bilirubin levels,improve the biochemical indexes and relieve some clinical symptoms.Moreover it is well tolerated for patients and there were no effect on serum albumin and coagulation.It can improve MELD score of liver function and APACHEII.

Effect of Hemodialysis with Plasma-based Dialysate Plus High Volume Hemofiltration on Serum Bilirubin and Plasma Cytokines in Patients with Liver Failure

[Effects of Interim Hemodialysis on Survival and Clinical Outcomes in Patients with Maintenance Peritoneal Dialysis].

Hemodialysis with Plasma-Based Dialysate -- a New Blood Purification Modality for Hyperbilirubinemia

Effects of Hemoperfusion Adsorption And/or Plasma Exchange in Treatment of Severe Viral Hepatitis: A Comparative Study

Plasma Exchange-Centered Artificial Liver Support System in Hepatitis B Virus-Related Acute-on-chronic Liver Failure: a Nationwide Prospective Multicenter Study in China.

[Clinical Research of Plasma Exchange with Continuous Veno-Venous Hemofiltration in Treating Mid- and Late-Stage Chronic Severe Viral Hepatitis B Patients].

Analysis of Clinical Effect of Continuous Plasma Diafiltration for the Therapy of Liver Failure

A Clinical Study on the Treatment of Severe Hepatitis by a Combined Artificial Liver.

Effect of high-flux hemodialysis on delayed hepatitis B virus vaccination response in hemodialysis patients.

Combined CVVH-bilirubin Adsorption Therapy on Patients with Hyperbilirubinemia

Primary Clinical Experience in High Risk Uremic Patients Converted from Conventional to Short Daily Hemodialysis

Comparison of Plasma Exchange with Different Membrane Pore Sizes in the Treatment of Severe Viral Hepatitis

Changes of serum cytokine levels in patients with acute on chronic liver failure treated by plasma exchange.

Assessment of Resin Perfusion in Hepatic Failurein Vitroandin Vivo

Combination therapy of plasma perfusion and plasma exchange in patients with liver failure and hyperbilirubinemia

Superior dialytic removal of bilirubin and bile acids by free fatty acid displacement and its combination with albumin dialysis

Comparitive study of middle and mixed artificial livers in treatment of hepatic failure

Evaluation of Safety and Effectiveness of Domestically Produced High-Flux Dialyzer for Hemodialysis Patients

Blood Hemoperfusion with Resin Adsorption Combined Continuous Veno-Venous Hemofiltration for Patients with Multiple Organ Dysfunction Syndrome.

Studies on the depression of radioiodine uptake by the thyroid after phenothiazine administration. II. Effect of phenothiazine on the horse thyroid.

Peritoneal dialysis effectively removes toxic substances and improves liver functions of liver failure patients